Regeneron Pharmaceuticals Inc (REGN) Given “Outperform” Rating at Leerink Swann

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “outperform” rating reissued by equities researchers at Leerink Swann in a research note issued on Monday.

A number of other analysts have also issued reports on the stock. BTIG Research reissued a “buy” rating and set a $460.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Canaccord Genuity reissued a “hold” rating and set a $375.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. CIBC assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday. They set a “market perform” rating for the company. Oppenheimer Holdings Inc. assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They set a “hold” rating for the company. Finally, Vetr raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 target price for the company in a research note on Wednesday, March 15th. Fourteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $434.97.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.45% during mid-day trading on Monday, reaching $382.02. 566,392 shares of the company’s stock were exchanged. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96. The firm has a market capitalization of $40.29 billion, a P/E ratio of 49.62 and a beta of 1.44. The company’s 50-day moving average is $371.86 and its 200 day moving average is $379.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.01. The firm earned $1.23 billion during the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business’s revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.83 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current fiscal year.

var userip;Your IP Address: document.write(userip);

In related news, major shareholder Sanofi acquired 87,298 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. WFG Advisors LP increased its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares during the period. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the period. Live Your Vision LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $157,000. Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $160,000. Finally, Global X Management Co. LLC increased its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 68.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition
Obamacare Market in Iowa Hit Hard by Aetna
Obamacare Market in Iowa Hit Hard by Aetna


© 2006-2017 Ticker Report. Google+.